EMD-19002
XBB-4 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein
EMD-19002
Single-particle3.41 Å
Deposition: 29/11/2023Map released: 08/05/2024
Last modified: 13/11/2024
Sample Organism:
Homo sapiens,
Severe acute respiratory syndrome coronavirus 2,
Tequatrovirus T4
Sample: XBB-4 Fab in complex with SARS-COV-2 BA.2.12.1 Spike Glycoprotein
Fitted models: 8r8k
Deposition Authors: Duyvesteyn HME
,
Ren J ,
Stuart DI
Sample: XBB-4 Fab in complex with SARS-COV-2 BA.2.12.1 Spike Glycoprotein
Fitted models: 8r8k
Deposition Authors: Duyvesteyn HME
,
Ren J ,
Stuart DI
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.
Liu C,
Zhou D ,
Dijokaite-Guraliuc A ,
Supasa P,
Duyvesteyn HME ,
Ginn HM,
Selvaraj M,
Mentzer AJ ,
Das R,
de Silva TI,
Ritter TG,
Plowright M,
Newman TAH ,
Stafford L,
Kronsteiner B,
Temperton N ,
Lui Y,
Fellermeyer M,
Goulder P,
Klenerman P,
Dunachie SJ,
Barton MI,
Kutuzov MA,
Dushek O,
Fry EE,
Mongkolsapaya J,
Ren J ,
Stuart DI ,
Screaton GR
(2024) Cell Rep Med , 5 , 101553 - 101553
,
Dijokaite-Guraliuc A ,
Supasa P,
Duyvesteyn HME ,
Ginn HM,
Selvaraj M,
Mentzer AJ ,
Das R,
de Silva TI,
Ritter TG,
Plowright M,
Newman TAH ,
Stafford L,
Kronsteiner B,
Temperton N ,
Lui Y,
Fellermeyer M,
Goulder P,
Klenerman P,
Dunachie SJ,
Barton MI,
Kutuzov MA,
Dushek O,
Fry EE,
Mongkolsapaya J,
Ren J ,
Stuart DI ,
Screaton GR
(2024) Cell Rep Med , 5 , 101553 - 101553
Grant Support:
- Wellcome Trust: 203141/A/16/Z (United Kingdom)
- Wellcome Trust: 101122/Z/13/Z (United Kingdom)
- CAMS Innovation Fund for Medical Sciences (CIFMS): 2018-I2M-2-002 (United Kingdom)
- Medical Research Council (MRC, United Kingdom): MR/N00065X/1 (United Kingdom)